The credibility of the clinical trial results for an experimental Alzheimer’s drug has been called into question following a critical inspection report by the Food and Drug Administration (FDA). What Happened: The FDA report, which was released under the Freedom of Information Act, highlighted several issues with the clinical trial work conducted by pharmacologist Hoau-Yan Wang at the City University of New York (CUNY), reported Science.org. Wang’s lab had analyzed samples of patients’ blood and cerebrospinal fluid from a key trial of the drug, simufilam, developed by his longtime collaborator…